Cargando…
Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders
A recent report showed that most pediatric cases of non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal disorders (EGIDs) (non-EoE EGIDs) are persistent and severe compared with those of EoE, thus requiring further effective therapeutic approaches. In this study, we present the first ca...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856177/ https://www.ncbi.nlm.nih.gov/pubmed/36671497 http://dx.doi.org/10.3390/biom13010112 |
_version_ | 1784873559934369792 |
---|---|
author | Arakawa, Naoya Yagi, Hisako Shimizu, Mariko Shigeta, Daisuke Shimizu, Akihiko Nomura, Shigeru Takizawa, Takumi Yamada, Yoshiyuki |
author_facet | Arakawa, Naoya Yagi, Hisako Shimizu, Mariko Shigeta, Daisuke Shimizu, Akihiko Nomura, Shigeru Takizawa, Takumi Yamada, Yoshiyuki |
author_sort | Arakawa, Naoya |
collection | PubMed |
description | A recent report showed that most pediatric cases of non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal disorders (EGIDs) (non-EoE EGIDs) are persistent and severe compared with those of EoE, thus requiring further effective therapeutic approaches. In this study, we present the first case based on a systematic search of non-EoE EGID for which tolerance to causative foods and histological and symptomatic improvements were achieved following dupilumab administration, after elimination diets and omalizumab and mepolizumab treatments. Driven by this case, we investigated the efficacies of biological treatments in non-EoE EGID cases based on the patient studied herein, and other patients identified in the conducted systematic review. Seven articles, including five different biologics, were reviewed. Both clinical efficacies and impact differences among the targeted molecules are demonstrated in this study. Our findings show that dupilumab may affect mechanisms that can suppress symptoms induced by offending foods that are different from those induced by other biologics as identified in the conducted systematic review. Additional studies are required to address the unmet needs of non-EoE EGID treatments. |
format | Online Article Text |
id | pubmed-9856177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98561772023-01-21 Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders Arakawa, Naoya Yagi, Hisako Shimizu, Mariko Shigeta, Daisuke Shimizu, Akihiko Nomura, Shigeru Takizawa, Takumi Yamada, Yoshiyuki Biomolecules Communication A recent report showed that most pediatric cases of non-eosinophilic esophagitis (EoE) eosinophilic gastrointestinal disorders (EGIDs) (non-EoE EGIDs) are persistent and severe compared with those of EoE, thus requiring further effective therapeutic approaches. In this study, we present the first case based on a systematic search of non-EoE EGID for which tolerance to causative foods and histological and symptomatic improvements were achieved following dupilumab administration, after elimination diets and omalizumab and mepolizumab treatments. Driven by this case, we investigated the efficacies of biological treatments in non-EoE EGID cases based on the patient studied herein, and other patients identified in the conducted systematic review. Seven articles, including five different biologics, were reviewed. Both clinical efficacies and impact differences among the targeted molecules are demonstrated in this study. Our findings show that dupilumab may affect mechanisms that can suppress symptoms induced by offending foods that are different from those induced by other biologics as identified in the conducted systematic review. Additional studies are required to address the unmet needs of non-EoE EGID treatments. MDPI 2023-01-05 /pmc/articles/PMC9856177/ /pubmed/36671497 http://dx.doi.org/10.3390/biom13010112 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Arakawa, Naoya Yagi, Hisako Shimizu, Mariko Shigeta, Daisuke Shimizu, Akihiko Nomura, Shigeru Takizawa, Takumi Yamada, Yoshiyuki Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders |
title | Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders |
title_full | Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders |
title_fullStr | Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders |
title_full_unstemmed | Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders |
title_short | Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders |
title_sort | dupilumab leads to clinical improvements including the acquisition of tolerance to causative foods in non-eosinophilic esophagitis eosinophilic gastrointestinal disorders |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856177/ https://www.ncbi.nlm.nih.gov/pubmed/36671497 http://dx.doi.org/10.3390/biom13010112 |
work_keys_str_mv | AT arakawanaoya dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders AT yagihisako dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders AT shimizumariko dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders AT shigetadaisuke dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders AT shimizuakihiko dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders AT nomurashigeru dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders AT takizawatakumi dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders AT yamadayoshiyuki dupilumableadstoclinicalimprovementsincludingtheacquisitionoftolerancetocausativefoodsinnoneosinophilicesophagitiseosinophilicgastrointestinaldisorders |